Page 227 - Genentech News Today

– Updated data from the Phase III POLARIX study continue to demonstrate a statistically significant reduction in the risk of disease worsening or death for people with previously untreated diffuse large B-cell lymphoma (DLBCL) –– Patients receiving Polivy plus R-CHP for DLBCL reported similar health-related quality...

Unlike most other Alzheimer’s prevention trials, this one will enroll people up to 25 years before the expected onset of dementia. Some participants could be as young as 18.

/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new and updated data across clinical and real-world studies in chronic lymphocytic leukemia (CLL)....

/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new and updated data across clinical and real-world studies in chronic lymphocytic leukemia (CLL)....

Unlike most other Alzheimer’s prevention trials, this one will enroll people up to 25 years before the expected onset of dementia. Some participants could be as young as 18.

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that the CONTACT-01 study did not meet its primary endpoint of overall survival at the final analysis. CONTACT-01 is a phase 3 trial evaluating cabozantinib (CABOMETYX®) in combination with atezolizumab (TECENTRIQ®) versus docetaxel in p...

The annual meeting of the American College of Rheumatology was held this year from Nov. 10 to 14 in Philadelphia and attracted participants from around the world, including rheumatology specialists, physicians, scientists, and other health professionals. The conference featured presentations focusing on the latest advances in the diagnosis and treatment of arthritis as well as

NEW YORK and MAINZ, GERMANY, DECEMBER 9, 2022 - Pfizer Inc.(Nasdaq: BNTX) today announced the companies have received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for their mRNA-based

‘When I started in IR, I told my wife I would stay in the job for five years – no more,’ says Dr Karl Mahler, who not only stuc

Genentech has voluntarily withdrawn the US indication for Tecentriq (atezolizumab) for previously untreated urothelial carcinoma.